Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Dr. Paul A. Barsanti , Ph.D., has joined ...
IDEAYA Biosciences (NASDAQ: IDYA ) announces that, based on FDA feedback, it will initiate a 60-subject Phase 2 single-arm clinical trial evaluating lead candidate IDE196 as monotherapy for the treatment of metastatic uveal melanoma (MUM) this quarter. More news on: IDEAYA Biosciences, I...
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provid...
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced t...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose last week from 3,267.22 points on Monday’s (September 16) open to 3,319.26 points as of 12:37 p.m. EDT on Friday (September 20). On Monday, Alder BioPharmaceuticals (NASDAQ: ALDR ) announced that it is going to be acquired by D...
Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $14 (141% upside) price target at Oppenheimer. Shares up 4% premarket. More news on: Aurinia Pharmaceuticals Inc., Homology Medicines, Inc., IDEAYA Biosciences, Inc., Healthcare stocks news, Stocks on ...
IDEAYA Biosciences (NASDAQ: IDYA ): Q2 GAAP EPS of -$1.30 misses by $0.75 . More news on: IDEAYA Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , Aug. 12, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a b...
IDEAYA Biosciences (NASDAQ: IDYA ) announces promotions of Paul A. Stone, J.D., as Chief Financial Officer (CFO), Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A., as Vice President, Development Operations. More news on: IDEAYA Biosciences, Inc., Health...
SOUTH SAN FRANCISCO, Calif. , July 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions of Paul A. Stone , J.D., as...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen PR Newswire Option for an exclusive worldwide license for potential first-in class B7H3/PTK7 topo-I-payload bispecific antibod...
Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program B7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, color...
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...